Vol. 1 No. 11 (2021)
Reimbursement Reviews

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

Published November 3, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ELX-TEZ-IVA (Trikafta) and ELX 100 mg, TEZ 50 mg, IVA 75 mg (combination tablet), and 150 mg IVA (tablet); oral.
  • Indication: Treatment of cystic fibrosis in patients aged ≥ 12 years who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.